JPMorgan analyst Anupam Rama raised the firm’s price target on Apellis (APLS) to $37 from $36 and keeps an Overweight rating on the shares. The firm’s survey of 23 nephrologists shows Empaveli is well positioned for “meaningful” share gain.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS: